Product
EFG PH20 SC
1 clinical trial
6 indications
Indication
MyositisIndication
Idiopathic Inflammatory MyopathyIndication
DermatomyositisIndication
polymyositisIndication
Immune-Mediated Necrotizing MyopathyIndication
Antisynthetase SyndromeClinical trial
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory MyopathyStatus: Recruiting, Estimated PCD: 2027-09-01